Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Charles Schwab Investment Management Inc. lifted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 3.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,669 shares of the company’s stock after purchasing an additional 7,129 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.23% of Aquestive Therapeutics worth $750,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new stake in Aquestive Therapeutics in the 4th quarter worth approximately $115,000. MONECO Advisors LLC purchased a new position in shares of Aquestive Therapeutics during the fourth quarter worth approximately $156,000. New York State Common Retirement Fund lifted its holdings in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the last quarter. Harvey Capital Management Inc. boosted its stake in shares of Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares in the last quarter. Finally, Financial Advocates Investment Management grew its holdings in shares of Aquestive Therapeutics by 28.2% during the 4th quarter. Financial Advocates Investment Management now owns 50,000 shares of the company’s stock valued at $178,000 after purchasing an additional 11,000 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Stock Down 4.0 %

Shares of AQST stock opened at $2.90 on Tuesday. The firm has a market capitalization of $286.73 million, a price-to-earnings ratio of -6.44 and a beta of 2.76. The stock has a fifty day moving average of $2.99 and a 200 day moving average of $3.93. Aquestive Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. Equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AQST. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target for the company. Lake Street Capital lowered their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Monday, March 10th. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics presently has an average rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.